Advertisement

Multiple Sclerosis Therapy

  • Andrew R. Pachner
Chapter

Abstract

The history of multiple sclerosis therapy is generally one of futility, consisting of many far-fetched remedies, some of which have been painful or harmful or both. This is not surprising given the variability of the disease among patients, and even within the same patients, and considering the relative inability of current therapy to reverse the disease. However, significant advances have been made in MS therapy, which have made McAlpine’s pessimistic statement in 1965 outdated. The pessimism of previous times has been replaced by a flurry of attempts to optimize modern clinical trial design to identify effective treatments. These attempts, which have come from a massive amount of investment by pharmaceutical companies and the extensive efforts of neurologists and allied health care workers, have led to the discovery of many effective therapies. These therapies can be divided into two general categories. This chapter first covers “disease-modifying drugs (DMDs),” therapies which affect the underlying disease process. Next “symptomatic therapies” are discussed, including life-style changes which can benefit the patient.

Keywords

Experimental Autoimmune Encephalomyelitis Botulinum Toxin Progressive Multifocal Leukoencephalopathy Glatiramer Acetate Progressive Multifocal Leukoencephalopathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Ebers GC, Heigenhauser L, Daumer M, Lederer C, Noseworthy JH. Disability as an outcome in MS clinical trials. Neurology. 2008;71(9):624–31.PubMedCrossRefGoogle Scholar
  2. 2.
    Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402–15.PubMedCrossRefGoogle Scholar
  3. 3.
    Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000;343(13):898–904.PubMedCrossRefGoogle Scholar
  4. 4.
    Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343(20):1430–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability. Brain. 2010;133(Pt 7):1914–29.PubMedCrossRefGoogle Scholar
  6. 6.
    Beck RW, Cleary PA, Anderson Jr MM, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992;326(9):581–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Pachner AR, Warth JD, Pace A, Goelz S. Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study. Neurology. 2009;73(18):1493–500.PubMedCrossRefGoogle Scholar
  8. 8.
    Filippini G, Munari L, Incorvaia B, et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet. 2003;361(9357):545–52.PubMedCrossRefGoogle Scholar
  9. 9.
    Pachner AR. An improved ELISA for screening for neutralizing anti-IFN-beta antibodies in MS patients. Neurology. 2003;61(10):1444–6.PubMedGoogle Scholar
  10. 10.
    Pachner AR, Steiner I. The multiple sclerosis severity score (MSSS) predicts disease severity over time. J Neurol Sci. 2009;278(1–2):66–70.PubMedCrossRefGoogle Scholar
  11. 11.
    Pachner AR, Dail D, Pak E, Narayan K. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies. J Neuroimmunol. 2005;166(1–2):180–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Teitelbaum D, Meshorer A, Hirshfeld T, Arnon R, Sela M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol. 1971;1(4):242–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Karussis D, Teitelbaum D, Sicsic C, Brenner T. Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy. J Neuroimmunol. 2010;220(1–2):125–30.PubMedCrossRefGoogle Scholar
  14. 14.
    Brenner T, Arnon R, Sela M, et al. Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuro­immunol. 2001;115(1–2):152–60.PubMedCrossRefGoogle Scholar
  15. 15.
    Rubio-Terres C, Dominguez-Gil Hurle A. [Cost-utility analysis of relapsing-remitting multiple sclerosis treatment with azathioprine or interferon beta in Spain]. Rev Neurol. 2005;40(12):705–10.PubMedGoogle Scholar
  16. 16.
    Casetta I, Iuliano G, Filippini G. Azathioprine for multiple sclerosis. Cochrane Database Syst Rev. 2007;(4):CD003982.Google Scholar
  17. 17.
    Ransohoff RM. Natalizumab for multiple sclerosis. N Engl J Med. 2007;356(25):2622–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry. 1997;62(2):112–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002;360(9350):2018–25.PubMedCrossRefGoogle Scholar
  20. 20.
    Marriott JJ, Miyasaki JM, Gronseth G, O’Connor PW. Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2010;74(18):1463–70.PubMedCrossRefGoogle Scholar
  21. 21.
    Boster A, Edan G, Frohman E, et al. Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet Neurol. 2008;7(2):173–83.PubMedCrossRefGoogle Scholar
  22. 22.
    Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416–26.PubMedCrossRefGoogle Scholar
  23. 23.
    Conway D, Cohen JA. Combination therapy in multiple sclerosis. Lancet Neurol. 2010;9(3):299–308.PubMedCrossRefGoogle Scholar
  24. 24.
    Kesselring J, Beer S. Symptomatic therapy and neurorehabilitation in multiple sclerosis. Lancet Neurol. 2005;4(10):643–52.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Andrew R. Pachner
    • 1
  1. 1.Department of Neurology and Neuroscience New Jersey Medical SchoolUniversity of Medicine and Dentistry of New JerseyNewarkUSA

Personalised recommendations